Kiadis Pharma Raises EUR 10 Million in Financing Round
|| Print ||
|Tuesday, 20 November 2012 11:00 (UTC + 1)|
Amsterdam, The Netherlands, November 20, 2012 / B3C newswire / – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has raised EUR 10 million in an equity financing round. This round was led by the Company’s largest shareholder LSP (Life Sciences Partners) and supported by a large investment from DFJ-Esprit. Other investors included Alta Partners, Quest for Growth and NOM. The financing will enable Kiadis Pharma to perform a confirmatory multi-center Phase II proof-of-concept study with its lead product ATIR™, and to prepare a pivotal Phase II/III study.
Manfred Ruediger, PhD, CEO of Kiadis Pharma, commented: “We are delighted with the enthusiastic support from existing and new investors, which attests to the exciting clinical data generated for ATIR™ so far and to the progress the Company has achieved over the last year. We are determined to advance ATIR™ in close cooperation with our clinical investigators in North America and Europe.”
Those T-cells in a haploidentical graft which would cause Graft-versus-Host-Disease (GvHD) are selectively eliminated using proprietary technology to produce ATIR™. ATIR™ is administered as an adjunctive treatment on top of a haploidentical stem cell transplantation enhancing early immune reconstitution without causing GvHD.
In a Phase I/II study with ATIR™, safety and proof of concept were provided in terms of absence of grade III/IV GvHD, reduced rates of infection, reduced Transplant Related Mortality and improved Overall Survival. ATIR™ has been granted Orphan Drug Designation both in the EU and the USA. Together, both regions represent a combined primary market potential of more than EUR 1 billion per year.
About Kiadis Pharma
The Company is collaborating with renowned centers in Europe, Canada and the United States to further develop ATIR™. Kiadis Pharma is based in Amsterdam, The Netherlands.